Diclofenac hydroxyethylpyrrolidine

Drug Profile

Diclofenac hydroxyethylpyrrolidine

Alternative Names: Effigel; Flector EP Tissugel; Flector Patch; Flector Tissugel

Latest Information Update: 22 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator IBSA
  • Developer IBSA; Pfizer
  • Class Analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 01 May 2014 Institut Biochemique SA plans a phase IV trial for Pain (In children with soft tissue injuries) in USA (NCT02132247)
  • 01 Mar 2011 King Pharmaceuticals has been acquired by Pfizer
  • 31 Dec 2008 Alpharma has been acquired by King Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top